LUMENIS

A BRIGHT SOLUTION FOR DRY EYES

OptiLIGHT OptiPLUS

ELEVATING DRY EYE MANAGEMENT

LUMENIS PUTS THE POWER TO MANAGE DRY EYE DISEASE IN THE PALM OF YOUR HAND

Do your patients suffer from dry, gritty, watery or burning eyes?
Dry eye disease affects about 49M Americans,[1] impacting vision and quality of life and the outcomes of ophthalmic surgeries.

Introducing the first and only light Therapy, FDA-approved for management of dry eye disease due to meibomian gland dysfunction (MGD), the leading cause of dry eye disease.[2] With clinically proven, patented technologies, the power for treating dry eye disease is in the palm of your hand. Get the safe, precise, elegant procedure you want and the comfortable, effective therapy patients need to manage dry eye disease with OptiLIGHT.

Complement your OptiLIGHT treatments with OptiPLUS and empower your practice with innovative, FDA-cleared, dual frequency RF technology. Developed specifically for you, OptiPLUS enables you to deliver efficient and safe heating of different skin layers, enhance clinical outcomes and expand your line of aesthetic treatments.

EXPERIENCE THE LUMENIS DIFFERENCE

Take the next step in your professional and clinical success with the innovators who brought you IPL for dry eye. Lumenis is your trusted ally in your journey to professional development, clinical success, and business expansion, while setting the highest standards in eye care for years to come.

OptiLIGHT

OptiPLUS

OptiLIGHT STATE OF THE ART TECHNOLOGY TRANSFORMS DRY EYE MANAGEMENT

FIRST AND ONLY, FDA APPROVED IPL FOR DED DUE TO MGD

Proven medical outcomes delivered through Lumenis' substantiated protocol.[16]

MULTI-FACTORIAL TREATMENT FOR A MULTI-FACTORIAL DISEASE

Root-cause treatment, clinically validated to target inflammation due to MGD.

CURATED FOR EYE CARE PROVIDERS

Specialty designed user interface and a signature hand-piece for precise application in delicate contours.

PATENTED OPT™ TECHNOLOGY

With the Patented Optimal Pulse Technology (OPT™) you can deliver targeted, precise and controlled treatment. The energy you set is the energy you get — optimal energy with a no-spike consistency.

OptiLIGHT BREAKS THE VICIOUS CYCLE OF INFLAMMATION

- Decreases the level of pro-inflammatory mediators to inhibit inflammation [3]
- Alleviates the abnormal blood vessels that perpetuate inflammation [5,6]
- Decreases the population of Demodex mites, which stimulate infection and boost bacterial load on the eyelids [7]
- Restores meibomian glands functionality [4,8]
- Increases tear breakup time [9]

OptiLIGHT

SAFETY AND EFFICACY BACKED BY SCIENCE

DECREASE INFLAMMATORY MARKERS[3]



IMPROVES TEAR BREAKUP TIME[9]



All clinical studies referred here were conducted with Lumenis IPL with OPT™.

IMPROVES OCULAR SURFACE DISEASE INDEX (OSDI)[15]



IMPROVES MODIFIED MEIBOMIAN GLAND SCORE (mMGS)[15]



The clinical study referred here was conducted with Lumenis IPL with OPT™ and Lumenis dual frequency RF technology.

REACH DIFFERENT SKIN LAYERS WITH OPTIPLUS' FDA-CLEARED DUAL FREQUENCY RF TECHNOLGY

The essential addition to OptiLIGHT

GROUNDBREAKING DUAL FREQUENCY TECHNOLOGY

Harness the potential of proprietary, innovative, dual frequency RF technology to precisely deliver heat across skin tissue layers, to both target the meibomian glands and enhance collagen production.[10, 13, 15]

ENHANCED CLINICAL RESULTS

Leverage a first of its kind pairing of dual frequency RF and OPT™ technologies to significantly improve the number of expressible meibomian glands, meibum clarity and symptoms.[15]

EXPANDED AESTHETIC BENEFITS

Give your patients the solution they're looking for by unlocking aesthetic advancement and enhancing facial skin rejuvenation and tightening.[10, 11, 13]

REVOLUTIONARY, DEDICATED RF DEVICE

Seamlessly augment treatment options, boosting productivity and income potential with the unparalleled technology and expertise of a dedicated device.

TAILORED TREATMENTS

Provide quick, safe treatments for a wide range of skin types with OptiPLUS' pre-embedded settings and ergonomic, user-friendly handpieces.

BREAKTHROUGH MONOPOLAR APPLICATION

Unique monopolar electrode ensures optimized contact with every delicate curve and outline around the eye, for enhanced patient comfort and safety.[14]

DUAL FREQUENCY RF TECHNOLOGY



OptiPLUS

OptiLIGHT TECHNICAL PARAMETERS

SYSTEM SPECIFICATIONS

Dimensions [without ResurFX]	51 X 56 X 52 cm (21 X 22 X 20.5 inches)
Dimensions [with ResurFX]	51 X 56 X 65 cm (21 X 22 X 25.6 inches)
Weight [without ResurFX]	45 kg / 99.2 lbs
Weight [with ResurFX]	60 kg / 132.3 lbs
Electrical requirements	100 - 240 VAC ±10%, 12A max, 50/60 Hz, single phase, dedicated line

OptiLIGHT

Spectrum	400-1200 nm
ExpertFilters*	OptiLIGHT; Acne: (400-600 & 800-1200); Vascular (530-650 & 900-1200); 515 nm, 560 nm; 590 nm; 615 nm; 640 nm; 695 nm; 755 nm;
Lightguides	15 × 35 mm; 8 × 15 mm
Maximal Fluence**	35 J/cm2
Pulse Duration**	4-20 ms
Pulse Delay**	5-150 ms
Pulse Characteristic	Multiple Sequential Pulsing
Repetition Rate	Up to 1 Hz
Spot Size	35×15 mm; 15×8 mm, 6.4mm Ø
Cooling	Continuous contact for IPL handpiece

* OptiLIGHT filter is received complementary with the system. Other filters can be purchased separately
** For upgraded IPL aesthetic configuration.
*** Indications for use may vary according to local registrations and approvals.

RISKS AND WARNING (NON-INCLUSIVE LIST):

Indication for Use: In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). This indication is intended for Fitzpatrick skin types I-V.

In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD), also known as evaporative dry eye or lipid deficiency dry eye, in patients 22 years of age and older with moderate to severe signs and symptoms of DED due to MGD and with Fitzpatrick skin types I-IV. IPL is to be applied only to skin on the malar region of the face, from tragus to tragus including the nose (eyes should be fully covered by protective eyewear). IPL is intended to be applied as an adjunct to other modalities, such as meibomian gland expression, artificial tear lubricants and warm compresses. The indications are only relevant where they were approved by the Regulatory Authorities.

Treatment with OptiLIGHT is contraindicated for patients with the following conditions in the Treatment area: Ocular surgery or eyelid surgery or Neuro-paralysis within 6 months prior to the first treatment; Uncontrolled eye disorders affecting the ocular surface; Pre-cancerous lesions, skin cancer or pigmented lesions; Uncontrolled infections or uncontrolled immunosuppressive diseases; Recent Ocular infections; History of cold sores or rashes in the perioral area, including: Herpes simplex 1 & 2, Systemic Lupus erythematosus and porphyria; Use of photosensitive medication and/or herbs that may cause sensitivity within 3 months prior to the first IPL session; Recent radiation therapy to the head or neck or planned radiation therapy; Recent treatment with chemotherapeutic agent or planned chemotherapy; History of migraines, seizures or epilepsy. Patients eyes must be completely occluded during the treatment. Please refer to the operator manual for a complete list of intended use, contraindications and risks.

The following possible side effects can occur following IPL treatments: Pain/discomfort, damage to natural skin texture, change of pigmentation, scarring, excessive edema, fragile skin, bruising, burns, pruritus and xerosis. Please refer to the user manual or ask your doctor for a complete list of intended use, contraindications and risks.

LUMENIS BE LTD.
Yokneam Industrial Park
Hakidma Street 9, P.O.B. #426
Yokneam 2069236, ISRAEL
Tel: +972 77 959 9000
Fax: 077-9599001

LUMENIS (GERMANY) GMBH
Heinrich-Hertz-Str 3 D-63303
Dreieich-Dreieichenhain
Germany
Tel: +49 (0) 6103 8335 0

AMERICAS
San Jose, CA, USA
Tel: +1 408 764 3000
+1 877 586 3647
Fax: +1 408 764 3999

JAPAN
Tokyo, Japan
Tel: +81 3 4431 8300
Fax: +81 3 4431 8301

ASIA / PACIFIC
Beijing, China
Tel: +86 10 5737 6677
Gurgaon, India
Tel: +91 124 422 07 95
Kowloon, Hong Kong
Tel: +852 217 428 00
Fax: +852 272 251 51

EMEA
Dreieich Dreieichenhain, Germany
Tel: +49 6103 8335 0
Fax: +49 6103 8335 300
Roma (RM), Italy
Tel: +39 06 90 75 230
Fax: +39 06 90 75 269
Hertfordshire, UK
Tel: +44 20 8736 4110
Fax: +44 20 8736 4119

CE 0483

Lumenis.com/OptiLIGHT

OptiLIGHT BY LUMENIS

OptiPLUS TECHNICAL PARAMETERS

SYSTEM SPECIFICATIONS

FocalRF Emission Frequency (±1%)	470 kHz, 1 MHz, 2 MHz, 4 MHz, 6 MHz
Maximum Output Power (±10%)	250W
Display LCD Touch Screen	15”
Operative Mode	Automatic treatment presets, NuLogic & Manual
Temperature Range	From 35°C to 42°C ± 1°C
Mains	100-240 Vac; 50/60 Hz; 350W
Dimensions	127×55×60 cm (HxWxD) / 49.9 × 21.6 × 23.6"
Weight	Weight 44Kg / 97 lbs
Safety Class	Class I - type BF
Capacitive Coated Electrodes*	ø10 mm, ø20 mm, ø30 mm, ø40 mm, ø60 mm, ø70 mm,ø80 mm ø100 mm, ø40 mm with massage

*OptiPLUS ø 10mm and ø20mm electrodes are received complementary with the system. Other electrodes can be purchased separately for upgraded aesthetic configuration.

RISKS AND WARNING (NON-INCLUSIVE LIST):

Indication for Use: OptiPLUS is intended to provide topical heating to treat selected medical conditions such as for temporary relief of pain or muscle spasms and to increase local circulation on body and face. The device is also intended to provide, with a massage device, a temporary reduction in the appearance of cellulite.

Treatment with OptiPLUS is contraindicated for patients with the following conditions in the treatment area: OptiPLUS is unsuitable for anyone who is pregnant, has an infection or illness, or is heat sensitive. Treatment over cuts, wounds, piercings, and tattoos must be avoided and areas with injectable fillers and toxins left for a month before treatment. Patients with a metal implant or implanted device (e.g pacemaker) must consult with a qualified physician first. If deemed suitable, the return pad must be placed far away from the implant. Local, oral, or systemic anesthetics cannot be used before or during treatment as patients need to provide regular feedback to ensure their continued comfort. Insulate patients from metal objects, especially any in direct contact (e.g. the bed). A full practitioner consultation is always advisable.
The device is not intended to be used within the orbital rim or on the neck.

The following possible side effects can occur following RF treatments: Moderate burning sensation, burns, erythema, edema, blistering, moderate pain, purpura in exposure area, mild swelling, ear feeling clogged and jaw tightness.
Please refer to the operator manual for a complete list of intended use, contraindications, and risks.

Bios S.r.l
Via Guido Rossa 10/12 - 20055
Vimodrone (MI) - Italy
T +39 02 27304275 info@biosgroup.eu
F +39 02 27304276 www.biosgroup.eu

AMERICAS
San Jose, CA, USA
T +1 408 764 3000
+1 877 586 3647
F +1 408 764 3999

Lumenis.com/OptiPLUS

OptiPLUS BY LUMENIS

Studies cited here were performed with Lumenis IPL with OPT: 1. USA General Population 2018 Cross Sectional Study and Census.gov Population Clock – accessed August 2nd 2020. 2. Lemp MA et al. (2012), *Cornea* 2012;31(5):472-428. 3. Liu et al. (2017), *Am J Ophthalmol* 181-190. 4. Huo et al. (2021) Ann Transl Med 9(3):238. 5. Kassir et al. (2011) *J Cosmet Laser Ther* 13(5):216-222. 6. Papageorgiou et al. (2008) *Br J Dermatol* 159(3):628-632. 7. Zhang et al. (2019), Curr Eye Res. 44(3):250-256. 8. Rong et al (2018), *Photomed Laser Surg* 2018 Jun;36(6):326-332.. 9. Dell et al. (2017) *Clin Ophthalmol* 11:817-827. 10. Javate RM, Cruz RT Jr, Khan J, Trakos N, Gordon RE. Nonablative 4-MHz dual radiofrequency wand rejuvenation treatment for periorbital rhytides and midface laxity. Ophthalmic Plast Reconstr Surg. 2011 May-Jun;27(3):180-5. doi: 10.1097/IOP.0b013e3181fe8e5a. PMID: 21283035. 11. Rabkin JM, Hunt TK. Local heat increases blood flow and oxygen tension in wounds. Arch Surg. 1987 Feb;122(2):221-5. doi: 10.1001/archsurg.1987.01400140103014. PMID: 3813871. 12. Malanga GA, Yan N, Stark J. Mechanisms and efficacy of heat and cold therapies for musculoskeletal injury. Postgrad Med. 2015 Jan;127(1):57-65. doi: 10.1080/00325481.2015.992719. Epub 2014 Dec 15. PMID: 25526231. 13. Al-Atif H. Collagen Supplements for Aging and Wrinkles: A Paradigm Shift in the Fields of Dermatology and Cosmetics. Dermatol Pract Concept. 2022 Jan 1;12(1):e2022018. doi: 10.5826/dpc.1201a18. PMID: 35223163; PMCID: PMC8824545. 14. Green JB, Dover JS, Kaminer MS. Tolerability of a monopolar radiofrequency facial skin tightening procedure: An observational study. Cosmetic Dermatology. 2011 July;24(7):327-330 15. Chelnis J, Garcia CN, Hamza H. Multi-Frequency RF Combined with Intense Pulsed Light Improves Signs and Symptoms of Dry Eye Disease Due to Meibomian Gland Dysfunction. Clin Ophthalmol. 2023;17:3089-3102